Korea Bio-Gen Co.Ltd (318000) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Korea Bio-Gen Co.Ltd KRW 4,968, price KRW 2,770, upside +79.3%, quality 64 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Korea Bio-Gen Co.Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
KBG Corp. produces and supplies a range of fine chemicals in South Korea and internationally.
Show more
KBG Corp. produces and supplies a range of fine chemicals in South Korea and internationally. The company offers silicone chemicals, such as functional organosilanes, functional silicone polymers, silicone resins and intermediates, silicone pressure sensitive adhesives, and silicone materials for electronics; specialty chemicals, including polymerization inhibitors; and food additives, as well as silicon inorganic chemical materials, organic materials, bio-materials, and others. It serves electric and electronics, automobile, construction, chemical related industries of food and pharmaceuticals, petrochemicals, etc. The company was formerly known as Korea Bio-Gen Co.,Ltd. KBG Corp. was founded in 2001 and is headquartered in Cheonan-si, South Korea.
Stock analysis
Korea Bio-Gen Co.Ltd (318000) currently trades at 2,770 KRW, while our model-based Fair Value estimate is 4,968 KRW, implying the stock looks roughly 44.2% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of 7,007 KRW per share, and 22 of the 22 models we run sit above the 2,770 KRW price.
Bear case: the Earnings-Based group reads lowest at 3,274 KRW, and 0 of the 22 models stay below the price. Evidence for this calculation is medium.
Scenario range: 4,214 KRW (bear) to 6,210 KRW (bull), the price of 2,770 KRW sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 64/100 (solid quality), in the Basic Materials sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Korea Bio-Gen Co.Ltd reported revenue of 23.9B KRW in FY2025 versus 27.2B KRW in FY2021, a compound −3.2%/yr. Reported net income was 2.6B KRW in FY2025, compounding −10.3%/yr from FY2021.
Key figures
Market cap 24.1B KRW (≈ $16.9M) · P/S ratio 1.06 · Dividend yield 2.2% · Net margin 10.8% · Return on equity 6.2% · Return on assets (EBIT) 9.4% · Operating margin 13.4% · Revenue (TTM) 23.2B KRW.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).
What moves the price
The share trades about 51% below its 52-week high and 7% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Basic Materials peers we cover trades at −40% fair-value upside, at 79%, 318000 screens cheaper than that median.
Fair Value models
Bear 4,214 KRWFair Value 4,968 KRWBull 6,210 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.65/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−4.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.9%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.5%
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−5.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year−7.5%
Dividend (yield on the price)2.2%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.17% → 13%
⚠ Revenue per share shrinking 13.5%/yr over ~6Y (margins intact) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−34.5%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about −35.8% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Specialty Chemicals · 714 stocks
Beats the industry median on 8/9 measures
Overall it ranks above its industry peers.
Valuation
Quality Score64 · Top 25%
Fair Value upside+79% · Top 25%
Profitability
Return on equity (TTM)6% · Above median
Return on assets4% · Above median
Net margin (TTM)12% · Top 25%
Operating margin (TTM)13% · Above median
Growth and dividend
Revenue growth−12% · Bottom 25%
Dividend yield (TTM)2.2% · Above median
Valuation Multiplesvs Specialty Chemicals median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Korea Bio-Gen Co.Ltd (318000) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 4,968 KRW versus a price of 2,770 KRW, about +79% upside (undervalued).
What is the fair value of 318000?
Our model-based fair value for Korea Bio-Gen Co.Ltd is 4,968 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 2,770 KRW.
What is the quality score of 318000?
Korea Bio-Gen Co.Ltd has a Quality Score of 64/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Korea Bio-Gen Co.Ltd (318000)?
Our model-based price target is the fair value of 4,968 KRW (as of Sep 24, 2026) from 22 valuation models. Cautious scenario 4,214 KRW, optimistic scenario 6,210 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Korea Bio-Gen Co.Ltd stock forecast for 2026?
Our models put fair value at 4,968 KRW, about +79% upside versus a price of 2,770 KRW (undervalued). Cautious scenario 4,214 KRW, optimistic scenario 6,210 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Korea Bio-Gen Co.Ltd (318000)?
Korea Bio-Gen Co.Ltd reported trailing-twelve-month revenue of about 23.2B KRW (latest available figure, as of Sep 24, 2026).
Does Korea Bio-Gen Co.Ltd pay a dividend?
Korea Bio-Gen Co.Ltd currently shows a dividend yield of about 2.17% relative to its recent price (as of Sep 24, 2026).
What growth is priced into Korea Bio-Gen Co.Ltd (318000)?
For today's price to be fair in a discounted-cash-flow model, Korea Bio-Gen Co.Ltd would have to grow free cash flow by -34.5 % per year for five years (discount rate 8.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +3.9 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 318000 use?
Our models discount Korea Bio-Gen Co.Ltd at 8.9 %: a base by market capitalisation (nano), damped by beta 0.27, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Korea Bio-Gen Co.Ltd that is -34.5 % per year a year over ten years, using the same discount rate (8.9 %) and the same formula as our fair value.
How much growth has Korea Bio-Gen Co.Ltd (318000) delivered so far?
Over the past 5 years revenue at Korea Bio-Gen Co.Ltd grew +3.9 % a year. The price currently implies -34.5 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Korea Bio-Gen Co.Ltd (318000) growing?
The median revenue growth in the sector is +3.3 % a year. That is the yardstick for the growth priced into Korea Bio-Gen Co.Ltd (-34.5 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Korea Bio-Gen Co.Ltd (318000)?
The free-cash-flow yield on the price is 28.54 %: that much free cash flow Korea Bio-Gen Co.Ltd produces per unit of market value. When it exceeds the discount rate of our models (8.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Korea Bio-Gen Co.Ltd (318000)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Korea Bio-Gen Co.Ltd it is 4,968 KRW per share (as of Sep 24, 2026), against a price of 2,770 KRW. It is the blended result of 22 valuation models (cash flow, earnings, asset, dividend).
Is Korea Bio-Gen Co.Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 318000 trades below its calculated fair value: price 2,770 KRW, fair value 4,968 KRW, a gap of about +79% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 318000?
No. The price is what the market pays today (2,770 KRW); the fair value is what the company's own numbers justify (4,968 KRW). For Korea Bio-Gen Co.Ltd the two are 2,198 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Korea Bio-Gen Co.Ltd worth?
The market values Korea Bio-Gen Co.Ltd at about 24.1B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 2,770 KRW; our models calculate a fair value of 4,968 KRW per share.
What do the bullish and bearish scenarios say about 318000?
Our models span a range for Korea Bio-Gen Co.Ltd: cautious scenario 4,214 KRW, base 4,968 KRW, optimistic 6,210 KRW per share (as of Sep 24, 2026, price 2,770 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Korea Bio-Gen Co.Ltd (318000)?
Balance-sheet figures for Korea Bio-Gen Co.Ltd (as of Sep 24, 2026): return on equity 6.2%. They feed the Quality Score of 64/100, which measures business quality independently of the share price.
How far is 318000 from its 52-week high?
Korea Bio-Gen Co.Ltd trades at 2,770 KRW, about 51% below its 52-week high of 5,643 KRW and 7% above the low of 2,595 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 4,968 KRW is for.
Which stocks are comparable to Korea Bio-Gen Co.Ltd?
From the same area (Basic Materials) we also value Linde plc, The Sherwin-Williams Company, Ecolab Inc, Air Products and Chemicals, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Korea Bio-Gen Co.Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price 2,770 KRW, calculated fair value 4,968 KRW (+79%), Quality Score 64/100, from 22 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 318000 calculated?
We run Korea Bio-Gen Co.Ltd through 22 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 4,968 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Korea Bio-Gen Co.Ltd currently trades 79 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Korea Bio-Gen Co.Ltd (318000)?
The closing price on Sep 23, 2026 was 2,770 KRW. Our model-based fair value is 4,968 KRW, about +79% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Korea Bio-Gen Co.Ltd right now?
The price is below even our cautious bear case (4,214 KRW). The market is more pessimistic than our downside scenario. Solid quality (64/100) at a price below fair value, the discount is the argument here, not the business quality.
Key figures of Korea Bio-Gen Co.Ltd
How large is the market capitalisation of Korea Bio-Gen Co.Ltd (318000)?
The market capitalisation of Korea Bio-Gen Co.Ltd is 24.1B KRW (≈ $16.9M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Korea Bio-Gen Co.Ltd (318000)?
The price-to-sales ratio of Korea Bio-Gen Co.Ltd is 1.06 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of Korea Bio-Gen Co.Ltd (318000)?
The dividend yield of Korea Bio-Gen Co.Ltd is 2.2%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Korea Bio-Gen Co.Ltd (318000)?
The net margin of Korea Bio-Gen Co.Ltd is 10.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Korea Bio-Gen Co.Ltd (318000)?
The return on equity (ROE) of Korea Bio-Gen Co.Ltd is 6.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Korea Bio-Gen Co.Ltd (318000)?
On an EBIT basis the return on assets of Korea Bio-Gen Co.Ltd is 9.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Korea Bio-Gen Co.Ltd (318000)?
The operating margin of Korea Bio-Gen Co.Ltd is 13.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Korea Bio-Gen Co.Ltd (318000)?
Revenue at Korea Bio-Gen Co.Ltd is growing −12.0% versus a year earlier (3y avg −0.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Korea Bio-Gen Co.Ltd (318000)?
Earnings per share at Korea Bio-Gen Co.Ltd are growing +53.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Korea Bio-Gen Co.Ltd (318000) carry?
The net debt of Korea Bio-Gen Co.Ltd is 2.0B KRW (fiscal year 2022, ≈ 0.3 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Korea Bio-Gen Co.Ltd in the live analysis
One click puts Korea Bio-Gen Co.Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
